中恒集团：获得两项药品注册证书

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for two drug registrations, indicating a positive development in the company's product portfolio and potential revenue growth [1] Group 1: Drug Approvals - The approved drugs include Nicorandil tablets (5mg) and Ketorolac Tromethamine injection (1ml:30mg) [1] - Nicorandil tablets are indicated for the treatment of angina pectoris, which addresses a significant market need in cardiovascular health [1] - Ketorolac Tromethamine injection is suitable for short-term treatment of moderate to severe acute postoperative pain, expanding the company's offerings in pain management [1]